Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500209 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Chelsi M Almodóvar-Rivera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Ubiquitin-Protein Ligases, Adaptor Proteins, Signal Transducing, Small Molecule Libraries. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of General Medical Sciences of the National Institutes of Health, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Proteolysis targeting chimeras (PROTACs) offer a promising therapeutic approach by leveraging the ubiquitin–proteasome system (UPS) to degrade target proteins. These heterobifunctional molecules consist of a target protein ligand, an E3 ligase ligand, and a linker. Among the limited E3 ligase ligands available, cereblon (CRBN) ligands are the most widely used. However, the stability and racemization of current chiral CRBN ligands pose challenges for developing CRBN‐recruiting PROTAC therapeutics. Herein, a partial PROTAC library is reported incorporating an aldehyde motif and various linkers into previously developed achiral phenyl dihydrouracil CRBN ligands, which offer improved stability and eliminate racemization issues. This library enables the rapid generation of fully functional PROTACs targeting Bruton's tyrosine kinase (BTK) by coupling the aldehyde motif with a hydrazide‐containing BTK ligand. Initial HiBiT assay (Promega) screening identifies nine hits capable of significant BTK degradation, with compound B1 emerging as the most potent degrader. A stable amide bioisostere, AM‐B1, is further developed, which induces significant antiproliferation and BTK degradation. Mechanistic studies confirm BTK degradation via the UPS. This study highlights the development of an achiral CRBN‐based partial PROTAC library and demonstrates a two‐stage strategy for rapid PROTAC development against BTK.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, WI, 53706, USA.
ORCID-Profile: Weiping Tang
Förderung
- National Institute of General Medical Sciences of the National Institutes of Health
- NIGMS NIH HHS
- NIH HHS
- Wisconsin Alumni Research Foundation (WARF)
- Lachman Institute for Pharmaceutical Development and UW Carbone Cancer Center
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Almodóvar-Rivera, C. M., Tandon, I., Mudududdla, R., Esguerra, P. N., Lucio-Acero, K., & Tang, W. (2025). Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. ChemMedChem. https://doi.org/10.1002/cmdc.202500209
Vancouver
Almodóvar-Rivera CM, Tandon I, Mudududdla R, Esguerra PN, Lucio-Acero K, Tang W. Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. ChemMedChem. 2025. doi:10.1002/cmdc.202500209
BibTeX
@article{AlmodvarRivera2025,
author = {Almodóvar-Rivera, Chelsi M and Tandon, Ira and Mudududdla, Ramesh and Esguerra, Paulina N and Lucio-Acero, Kevin and Tang, Weiping},
title = {Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500209}
}
EUVIMED